AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. LAB
  4. [Form 4] Standard BioTools Inc. Insider Trading Activity

[Form 4] Standard BioTools Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Standard BioTools (NASDAQ:LAB) submitted a routine Form 4 disclosing director Troy Cox received 94,592 restricted stock units (RSUs) that vest in full by June 20 2026 and a stock option for 125,660 shares at an exercise price of $1.05, vesting in 12 equal monthly installments beginning July 20 2025.

Following these grants, Cox鈥檚 beneficial ownership stands at 256,412 common shares. No shares were sold, and the filing contains no additional transactions or financial disclosures.

Standard BioTools (NASDAQ:LAB) ha presentato un modulo Form 4 ordinario che rivela che il direttore Troy Cox ha ricevuto 94.592 unit脿 azionarie vincolate (RSU) che maturano completamente entro il 20 giugno 2026 e un opzione su azioni per 125.660 azioni con un prezzo di esercizio di $1,05, che maturano in 12 rate mensili uguali a partire dal 20 luglio 2025.

Dopo queste concessioni, la propriet脿 effettiva di Cox ammonta a 256.412 azioni ordinarie. Non sono state vendute azioni e la comunicazione non contiene altre transazioni o informazioni finanziarie.

Standard BioTools (NASDAQ:LAB) present贸 un Formulario 4 rutinario que revela que el director Troy Cox 谤别肠颈产颈贸 94,592 unidades restringidas de acciones (RSU) que se consolidan por completo para el 20 de junio de 2026 y una opci贸n sobre acciones para 125,660 acciones con un precio de ejercicio de $1.05, que se consolidan en 12 cuotas mensuales iguales a partir del 20 de julio de 2025.

Tras estas concesiones, la propiedad beneficiosa de Cox es de 256,412 acciones comunes. No se vendieron acciones y la presentaci贸n no incluye otras transacciones ni divulgaciones financieras.

Standard BioTools (NASDAQ:LAB)電� 鞚挫偓 Troy Cox臧赌 94,592臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 靾橂牴頄堨溂氅�, 鞚措姅 2026雲� 6鞗� 20鞚缄箤歆� 鞝勳暋 旆摑霅橁碃, 125,660欤检潣 欤检嫕 鞓奠厴鞚� 頄夓偓 臧赌瓴� $1.05鞐� 攵�鞐皼鞎橃溂氅�, 2025雲� 7鞗� 20鞚茧秬韯� 12臧滌洈鞐� 瓯胳硱 毵れ洈 霃欖澕頃� 牍勳湪搿� 旆摑霅滊嫟瓿� 鞝曣赴鞝侅澑 Form 4毳� 鞝滌稖頄堧嫟瓿� 氚濏様鞀惦媹雼�.

鞚措煬頃� 攵�鞐� 鞚错泟, Cox鞚� 鞁れ 靻岇湢 欤检嫕 靾橂姅 256,412欤检潣 氤错喌欤�鞛呺媹雼�. 欤检嫕 毵る弰電� 鞐嗢棃鞙茧┌, 鞝滌稖靹滌棎電� 於旉岸� 瓯半灅雮� 鞛 瓿奠嫓臧赌 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.

Standard BioTools (NASDAQ:LAB) a soumis un formulaire 4 de routine indiquant que le directeur Troy Cox a re莽u 94 592 unit茅s d'actions restreintes (RSU) qui seront enti猫rement acquises d'ici le 20 juin 2026, ainsi qu'une option d'achat portant sur 125 660 actions 脿 un prix d'exercice de 1,05 $, acquise en 12 versements mensuels 茅gaux 脿 partir du 20 juillet 2025.

Suite 脿 ces attributions, la participation b茅n茅ficiaire de Cox s'茅l猫ve 脿 256 412 actions ordinaires. Aucune action n'a 茅t茅 vendue et le d茅p么t ne contient aucune autre transaction ni divulgation financi猫re.

Standard BioTools (NASDAQ:LAB) reichte ein routinem盲脽iges Formular 4 ein, das offenlegt, dass Direktor Troy Cox 94.592 eingeschr盲nkte Aktieneinheiten (RSUs) erhielt, die bis zum 20. Juni 2026 vollst盲ndig unverfallbar sind, sowie eine Aktienoption f眉r 125.660 Aktien zu einem Aus眉bungspreis von 1,05 $, die in 12 gleichen monatlichen Raten ab dem 20. Juli 2025 unverfallbar wird.

Nach diesen Zuteilungen h盲lt Cox nun 256.412 Stammaktien im wirtschaftlichen Eigentum. Es wurden keine Aktien verkauft, und die Einreichung enth盲lt keine weiteren Transaktionen oder finanzielle Offenlegungen.

Positive
  • None.
Negative
  • None.

Standard BioTools (NASDAQ:LAB) ha presentato un modulo Form 4 ordinario che rivela che il direttore Troy Cox ha ricevuto 94.592 unit脿 azionarie vincolate (RSU) che maturano completamente entro il 20 giugno 2026 e un opzione su azioni per 125.660 azioni con un prezzo di esercizio di $1,05, che maturano in 12 rate mensili uguali a partire dal 20 luglio 2025.

Dopo queste concessioni, la propriet脿 effettiva di Cox ammonta a 256.412 azioni ordinarie. Non sono state vendute azioni e la comunicazione non contiene altre transazioni o informazioni finanziarie.

Standard BioTools (NASDAQ:LAB) present贸 un Formulario 4 rutinario que revela que el director Troy Cox 谤别肠颈产颈贸 94,592 unidades restringidas de acciones (RSU) que se consolidan por completo para el 20 de junio de 2026 y una opci贸n sobre acciones para 125,660 acciones con un precio de ejercicio de $1.05, que se consolidan en 12 cuotas mensuales iguales a partir del 20 de julio de 2025.

Tras estas concesiones, la propiedad beneficiosa de Cox es de 256,412 acciones comunes. No se vendieron acciones y la presentaci贸n no incluye otras transacciones ni divulgaciones financieras.

Standard BioTools (NASDAQ:LAB)電� 鞚挫偓 Troy Cox臧赌 94,592臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 靾橂牴頄堨溂氅�, 鞚措姅 2026雲� 6鞗� 20鞚缄箤歆� 鞝勳暋 旆摑霅橁碃, 125,660欤检潣 欤检嫕 鞓奠厴鞚� 頄夓偓 臧赌瓴� $1.05鞐� 攵�鞐皼鞎橃溂氅�, 2025雲� 7鞗� 20鞚茧秬韯� 12臧滌洈鞐� 瓯胳硱 毵れ洈 霃欖澕頃� 牍勳湪搿� 旆摑霅滊嫟瓿� 鞝曣赴鞝侅澑 Form 4毳� 鞝滌稖頄堧嫟瓿� 氚濏様鞀惦媹雼�.

鞚措煬頃� 攵�鞐� 鞚错泟, Cox鞚� 鞁れ 靻岇湢 欤检嫕 靾橂姅 256,412欤检潣 氤错喌欤�鞛呺媹雼�. 欤检嫕 毵る弰電� 鞐嗢棃鞙茧┌, 鞝滌稖靹滌棎電� 於旉岸� 瓯半灅雮� 鞛 瓿奠嫓臧赌 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.

Standard BioTools (NASDAQ:LAB) a soumis un formulaire 4 de routine indiquant que le directeur Troy Cox a re莽u 94 592 unit茅s d'actions restreintes (RSU) qui seront enti猫rement acquises d'ici le 20 juin 2026, ainsi qu'une option d'achat portant sur 125 660 actions 脿 un prix d'exercice de 1,05 $, acquise en 12 versements mensuels 茅gaux 脿 partir du 20 juillet 2025.

Suite 脿 ces attributions, la participation b茅n茅ficiaire de Cox s'茅l猫ve 脿 256 412 actions ordinaires. Aucune action n'a 茅t茅 vendue et le d茅p么t ne contient aucune autre transaction ni divulgation financi猫re.

Standard BioTools (NASDAQ:LAB) reichte ein routinem盲脽iges Formular 4 ein, das offenlegt, dass Direktor Troy Cox 94.592 eingeschr盲nkte Aktieneinheiten (RSUs) erhielt, die bis zum 20. Juni 2026 vollst盲ndig unverfallbar sind, sowie eine Aktienoption f眉r 125.660 Aktien zu einem Aus眉bungspreis von 1,05 $, die in 12 gleichen monatlichen Raten ab dem 20. Juli 2025 unverfallbar wird.

Nach diesen Zuteilungen h盲lt Cox nun 256.412 Stammaktien im wirtschaftlichen Eigentum. Es wurden keine Aktien verkauft, und die Einreichung enth盲lt keine weiteren Transaktionen oder finanzielle Offenlegungen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cox Troy
(Last) (First) (Middle)
C/O STANDARD BIOTOOLS INC.
2 TOWER PLACE, STE 2000
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 A 94,592(1) A $0 256,412 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to buy) $1.05 06/20/2025 A 125,660 (2) 06/20/2035 Common Stock 125,660 $0 125,660 D
Explanation of Responses:
1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 20, 2026 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
2. The Option becomes exercisable in twelve equal monthly installments beginning on July 20, 2025, subject to the Reporting Person's continued service through the applicable vesting date.
/s/ Troy Cox by Tomone Tanaka, Attorney-in-Fact 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many RSUs did LAB grant to director Troy Cox on 06/20/2025?

The Form 4 reports 94,592 RSUs granted to Troy Cox.

What are the key terms of the new LAB stock option granted to Troy Cox?

The option covers 125,660 shares at an exercise price of $1.05, vesting monthly over one year and expiring on 06/20/2035.
Stock LAB logo
STANDARD BIOTOOLS INC

NASDAQ:LAB

LAB Rankings

#4468 Ranked by Market Cap
N/A Ranked by Dividends

LAB Latest News

Jul 21, 2025
Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025
Jun 23, 2025
Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
Jun 23, 2025
Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina
May 30, 2025
Standard BioTools to Host Inaugural 鈥淧roteomics Roundtable鈥� Webcast Series
May 6, 2025
Standard BioTools Reports First Quarter 2025 Financial Results

LAB Latest SEC Filings

Jun 24, 2025
[Form 4] Standard BioTools Inc. Insider Trading Activity
Jun 24, 2025
[Form 4] Standard BioTools Inc. Insider Trading Activity
Jun 24, 2025
[Form 4] Standard BioTools Inc. Insider Trading Activity
Jun 24, 2025
[Form 4] Standard BioTools Inc. Insider Trading Activity
Jun 24, 2025
[Form 4] Standard BioTools Inc. Insider Trading Activity

LAB Stock Data

523.80M
373.92M
1.86%
73.11%
3.81%
Medical Devices
Laboratory Analytical Instruments
United States
SOUTH SAN FRANCISCO